Composition comprising gv1001 for preventing or treating macular degeneration

The peptide GV1001 addresses the limited treatment options for dry age-related macular degeneration by reducing oxidative stress and cell degeneration, offering a therapeutic effect in both cellular and animal models, thus providing a potential solution for treating and preventing the condition.

WO2024237768A1PCT designated stage expired Publication Date: 2024-11-21GEMVAX & KAEL CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/095811
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for dry age-related macular degeneration are limited, with only one FDA-approved drug available, necessitating a need for effective prevention and treatment options that address retinal pigment epithelial cell degeneration and oxidative stress.

Method used

A pharmaceutical composition and health functional food containing the peptide GV1001, which reduces reactive oxygen species and inhibits retinal pigment epithelial cell degeneration, offering a therapeutic effect in both cell and mouse models of macular degeneration.

Benefits of technology

GV1001 effectively reduces cell degeneration and maintains epithelial properties, providing a promising treatment and prevention option for age-related macular degeneration by reducing oxidative stress and inhibiting epithelial-mesenchymal transition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024095811_21112024_PF_FP_ABST
    Figure KR2024095811_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating macular degeneration and, more specifically, to a pharmaceutical composition for preventing or treating macular degeneration, wherein the pharmaceutical composition exhibits an effect of reducing retinal degeneration, is safe for the living body, and has fewer side effects including abnormal reactions, by comprising a peptide having the amino acid sequence of SEQ ID NO: 1.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for preventing or treating macular degeneration comprising GV1001

[0001] The present invention relates to a composition for preventing or treating macular degeneration comprising GV1001.

[0002]

[0003] Age-related macular degeneration (AMD) is an eye disease that causes progressive vision loss, starting from the center of the field of vision, due to damage to the macula, the central part of the retina where images are focused, and can lead to blindness. Age-related macular degeneration can be divided into dry AMD, which is caused by the accumulation of cellular metabolic waste products such as drusen and amyloid beta (Aβ), and wet AMD, which causes vision loss due to bleeding or fluid leakage caused by the formation of new blood vessels.

[0004] Dry AMD occurs when persistent exposure to stressful situations, such as oxidative stress, leads to retinal cell death and degeneration. This cell death and degeneration weakens the dense retinal layer, and neovascularization, driven by secreted cytokines and growth factors, can lead to the development of wet AMD. Therefore, treatment in the dry AMD stage is crucial.

[0005] In the case of wet macular degeneration, it is known that the direct cause is the creation of new blood vessels by vascular endothelial growth factor (VEGF), and drugs that target VEGF, such as Eylea®, are currently used as treatment.

[0006] Unlike wet AMD, which has numerous commercially available treatments, there is currently only one FDA-approved drug for dry AMD. Therefore, the development of a dry AMD treatment that can control the early stages of AMD is urgently needed.

[0007] Accordingly, the inventors of the present invention completed the present invention as a result of extensive research to treat age-related macular degeneration by reducing reactive oxygen species (ROS) and reducing degeneration of retinal pigment epithelial cells (RPE cells).

[0008]

[0009] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating macular degeneration.

[0010] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating age-related macular degeneration.

[0011] The purpose of the present invention is to provide a kit for preventing or treating macular degeneration.

[0012] The purpose of the present invention is to provide a health functional food for preventing or improving macular degeneration.

[0013] The purpose of the present invention is to provide a health functional food for preventing or improving age-related macular degeneration.

[0014]

[0015] 1. A pharmaceutical composition for preventing or treating macular degeneration comprising a peptide having an amino acid sequence of sequence number 1.

[0016] 2. In the above 1, the pharmaceutical composition wherein the macular degeneration is age-related macular degeneration.

[0017] 3. In the above 1, the pharmaceutical composition prevents or treats macular degeneration by reducing degeneration of retinal pigment epithelial cells.

[0018] 4. A kit for preventing or treating macular degeneration, comprising any one of the pharmaceutical compositions 1 to 3 above; and instructions describing a method for preventing or treating macular degeneration.

[0019] 5. A kit according to the above 4, wherein the method for preventing or treating macular degeneration comprises a step of administering a pharmaceutical composition to a subject who has developed or is at risk of developing macular degeneration.

[0020] 6. A health functional food for preventing or improving macular degeneration, comprising a peptide having an amino acid sequence of sequence number 1.

[0021] 7. In the above 6, macular degeneration is a health functional food that is age-related macular degeneration.

[0022] 8. In the above 6, the health functional food is a health functional food that prevents or improves macular degeneration by reducing degeneration of retinal pigment epithelial cells.

[0023]

[0024] The pharmaceutical composition comprising the peptide having the amino acid sequence of SEQ ID NO: 1 of the present invention not only reduced cell degeneration in a retinal pigment epithelial cell model of age-related macular degeneration, but also exhibited inhibitory and / or therapeutic effects on retinal degeneration in a mouse model of age-related macular degeneration. Therefore, the pharmaceutical composition of the present invention is expected to be effective in the treatment, improvement, or prevention of macular degeneration.

[0025] The pharmaceutical composition and health functional food of the present invention are expected to be useful in preventing, improving, or treating macular degeneration by including GV1001 as an active ingredient, which has completed toxicity tests in numerous clinical trials and has been confirmed to be safe for side effects.

[0026] It is expected that the pharmaceutical composition, kit, and health functional food of the present invention will be able to provide economic or medical help to patients suffering from macular degeneration and their families in the future.

[0027] The present invention is expected to contribute to understanding the pathophysiology of macular degeneration by elucidating the mechanism of the pharmacological effect of GV1001 on macular degeneration and serve as a driving force for the development of new therapeutic agents in the future.

[0028]

[0029] Figure 1 shows the GV1001 administration timing and experimental schedule for the GV1001 pre-treatment animal experimental group used in the GV1001 short-term administration effect evaluation test.

[0030] Figure 2 shows the GV1001 administration timing and experimental schedule for the GV1001 post-treatment animal experimental group used in the GV1001 short-term administration effect evaluation test.

[0031] Figure 3 shows the timing of administration of the positive control drug and the experimental schedule used in the short-term administration effect evaluation test of GV1001.

[0032] Figure 4 shows the GV1001 administration timing and experimental schedule for the GV1001 pre-treatment animal experimental group used in the GV1001 long-term administration effect evaluation test.

[0033] Figure 5 shows the GV1001 administration timing and experimental schedule for the GV1001 post-treatment animal experimental group used in the GV1001 long-term administration effect evaluation test.

[0034] Figure 6 shows the results of confirming the efficacy of GV1001 in reducing reactive oxygen species.

[0035] Figure 7 shows the results of confirming the efficacy of GV1001 in reducing epithelial-mesenchymal transition.

[0036] Figures 8 and 9 show the results of confirming the efficacy of short-term administration of GV1001 in a mouse model of age-related macular degeneration.

[0037] Figures 10 and 11 show the results of confirming the efficacy of long-term administration of GV1001 in a mouse model of age-related macular degeneration.

[0038]

[0039] The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, comprising a peptide having an amino acid sequence of sequence number 1.

[0040] In the present invention, a peptide having an amino acid sequence of SEQ ID NO: 1 includes a functional equivalent thereof. The term "functional equivalent" refers to a peptide having at least 70%, 80%, 90%, or 95% sequence homology with the amino acid sequence of SEQ ID NO: 1 as a result of addition, substitution, or deletion of amino acids, and exhibiting substantially the same physiological activity as the peptide having the amino acid sequence of SEQ ID NO: 1. "Substantially the same physiological activity" refers to an activity involved in the prevention, improvement, or treatment of macular degeneration.

[0041] In the present invention, “macular degeneration” includes age-related macular degeneration, age-related macular degeneration, senile macular degeneration, myopic macular degeneration, and macular dystrophy.

[0042] In the present invention, “age-related macular degeneration” includes dry macular degeneration and wet macular degeneration.

[0043] In one embodiment, the macular degeneration may be age-related macular degeneration.

[0044] In one embodiment, the macular degeneration may be dry macular degeneration.

[0045] In the present invention, “prevention” means any act of inhibiting or delaying macular degeneration.

[0046] In the present invention, “treatment” means any action that improves or beneficially changes the symptoms of an individual suspected of having or having developed macular degeneration.

[0047] In one embodiment, the pharmaceutical composition of the present invention can prevent or treat macular degeneration by reducing reactive oxygen species.

[0048] In one embodiment, the pharmaceutical composition of the present invention can prevent or treat macular degeneration by reducing degeneration of retinal pigment epithelial cells.

[0049] In the present invention, “subject” means any animal, such as livestock and mice, that has developed or may develop macular degeneration, and may be a mammal, including a human.

[0050] The pharmaceutical composition of the present invention may be provided as a pharmaceutical composition containing the active ingredient alone or containing one or more pharmaceutically acceptable carriers, excipients or diluents.

[0051] The carrier, excipient or diluent that may be included in the pharmaceutical composition of the present invention may be, but is not limited to, lactose, dextrose, sucrose, dextrin, maltodextrin, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.

[0052]

[0053] The present invention provides a kit for preventing or treating macular degeneration, comprising a pharmaceutical composition for preventing or treating macular degeneration and instructions describing a method for preventing or treating macular degeneration.

[0054] In one embodiment, a method for preventing or treating macular degeneration may comprise administering a pharmaceutical composition of the invention to a subject who has developed or is at risk of developing macular degeneration.

[0055] In the present invention, “administration” means introducing a predetermined substance to an individual by an appropriate method.

[0056] The route of administration of the pharmaceutical composition of the present invention may be oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal, but is not limited thereto.

[0057] In one embodiment, the composition of the present invention may be administered orally or parenterally.

[0058] When administering the composition of the present invention parenterally, it is preferable to select an injection method such as external application to the skin or intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection, but is not limited thereto.

[0059] The pharmaceutical composition of the present invention may be a solid preparation for oral administration, such as a tablet, pill, powder, granule, or capsule.

[0060] The pharmaceutical composition of the present invention may be a liquid preparation for oral administration, such as a suspension, a solution, an emulsion, or a syrup.

[0061] The pharmaceutical composition of the present invention may be a preparation for parenteral administration, such as a sterile aqueous solution, non-aqueous solution, suspension, emulsion, lyophilized preparation or suppository.

[0062] In one embodiment, a method for preventing or treating macular degeneration may comprise administering a pharmaceutically effective amount of a pharmaceutical composition of the present invention to a subject having or at risk of developing macular degeneration.

[0063] In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat macular degeneration at a reasonable benefit / risk ratio applicable to medical treatment.

[0064] The pharmaceutically effective amount of the pharmaceutical composition of the present invention can be determined based on factors including the severity of macular degeneration, activity of the pharmaceutical composition, sensitivity of the subject or patient to the pharmaceutical composition, time of administration, route of administration and excretion rate, duration of treatment and concomitant medication, and other factors well known in the medical field, and can be appropriately selected by a person skilled in the art.

[0065] The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses, which can be readily determined by a person skilled in the art.

[0066]

[0067] The present invention provides a health functional food for preventing or improving macular degeneration, comprising a peptide having an amino acid sequence of sequence number 1.

[0068] The health functional food of the present invention refers to a food manufactured and / or processed in various forms to provide useful functionality to the human body.

[0069] The health functional food of the present invention can be included in various foods or medicines known in the art.

[0070] There are no specific limitations on the types of foods that can contain the health functional food of the present invention. For example, the health functional food of the present invention can be contained in meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.

[0071] The health functional food of the present invention includes all forms such as functional food, nutritional supplement, health food, and food additives, and these types of food can be manufactured in various forms according to conventional methods known in the art. For example, the health food can be manufactured in the form of a liquid drink for consumption, or can be ingested by being granulated, encapsulated, spherical tableted (pills, etc.), or powdered, and can also be manufactured in the form of a powder, capsule, soft capsule, tablet, gum, or adhesive-type liquid composition for consumption. In addition, functional foods include beverages (including alcoholic beverages), fruits and their processed foods (e.g., canned fruits, bottled fruits, jams, marmalades, etc.), fish, meat and their processed foods (e.g., ham, sausages, corned beef, etc.), breads and noodles (e.g., udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, taffy, dairy products (e.g., butter, cheese, etc.), edible vegetable oils, margarine, vegetable proteins, retort foods, frozen foods, seasonings, various seasonings (e.g., soybean paste, soy sauce, sauces, etc.).

[0072] The health functional food of the present invention may further include ingredients commonly added during food manufacturing, as long as it does not deviate from the ultimate purpose of the present invention, and may further include, for example, proteins, carbohydrates, fats, other nutrients, seasonings, and flavorings.

[0073] The health functional food of the present invention may additionally contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc.

[0074] The health functional food of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination.

[0075]

[0076] Hereinafter, the present invention will be described in detail with examples to specifically illustrate the invention. However, the following examples are provided merely to facilitate a better understanding of the present invention and are not intended to limit the scope of the present invention.

[0077]

[0078] Example

[0079] Using retinal pigment epithelial cells and a mouse model of age-related macular degeneration, we confirmed that GV1001 reduces damage to the retinal pigment epithelium. Furthermore, we conducted basic research to elucidate the molecular mechanisms underlying the pharmacological effects of GV1001 on macular degeneration.

[0080]

[0081] 1. Experimental method

[0082] 1.1 Synthesis of GV1001

[0083] A peptide consisting of 16 amino acids having the structural formula of the following chemical formula 1 and having the following sequence number 1 (GV1001) selected from human telomerase was synthesized.

[0084] <Chemical Formula 1>

[0085]

[0086] Peptide GV1001, sequence number 1, was prepared according to a conventional solid-phase peptide synthesis method. Specifically, the peptides were synthesized by coupling amino acids one by one from the C-terminus via Fmoc solid-phase peptide synthesis (SPPS) using ASP48S (Peptron, Inc., Daejeon, South Korea). The peptides were used with the first C-terminal amino acid attached to the resin, as follows:

[0087] NH2-Lys(Boc)-2-chloro-Trityl Resin

[0088] NH2-Ala-2-chloro-Trityl Resin

[0089] NH2-Arg(Pbf)-2-chloro-Trityl Resin

[0090] All amino acid starting materials used for peptide synthesis were N-terminally protected with Fmoc, and all residues were protected with acids such as Trt, Boc, t-Bu (t-butylester), and Pbf (2,2,4,6,7-pentamethyl dihydro-benzofuran-5-sulfonyl). Examples include:

[0091] Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Met-OH, Fmoc-Asn(Trt)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ahx-OH, Trt-Mercaptoacetic acid.

[0092] Coupling reagents used were HBTU [2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetamethylaminium hexafluorophosphate] / HOBt [N-Hydroxxybenzotriazole] / NMM [4-Methylmorpholine]. Fmoc removal was performed using piperidine in DMF at 20%. Cleavage cocktail [TFA (trifluoroacetic acid) / TIS (triisopropylsilane) / EDT (ethanedithiol) / H2O=92.5 / 2.5 / 2.5 / 2.5] was used to detach the synthesized peptide from the resin and remove the protecting group of the residue.

[0093] Each peptide was synthesized by repeatedly reacting the starting amino acids with amino acid protecting groups bound to a solid support, washing with a solvent, and deprotecting them. The synthesized peptides were excised from the resin, purified by HPLC, and confirmed to be synthesized by MS. The peptides were then lyophilized.

[0094] The specific synthesis process of GV1001 is described as follows.

[0095] 1) Coupling

[0096] Protected amino acid (8 equivalents) and coupling reagents HBTU (8 equivalents) / HOBt (8 equivalents) / NMM (16 equivalents) were dissolved in DMF and added to NH2-Lys(Boc)-2-chloro-Trityl Resin, and the mixture was reacted at room temperature for 2 hours and washed with DMF, MeOH, and DMF in that order.

[0097] 2) Fmoc deprotection

[0098] Piperidine in DMF (20% piperidine in DMF) was added and reacted twice at room temperature for 5 minutes, and washed in the order of DMF, MeOH, and DMF.

[0099] 3) The peptide backbone was created by repeating reactions 1 and 2.

[0100] 4) Cleavage: Cleavage cocktail was added to the peptide resin on which synthesis was completed to separate the peptide from the resin.

[0101] 5) Cooling diethyl ether was added to the obtained mixture, and the resulting peptide was precipitated by centrifugation.

[0102] 6) After purification by Prep-HPLC, the molecular weight was confirmed by LC / MS, and the product was frozen to manufacture a powder.

[0103]

[0104] 1.2 Verification of reduction in retinal pigment epithelial cell degeneration by GV1001

[0105] 1) Establishment of a cell model of age-related macular degeneration

[0106] Reactive oxygen species were generated by treating retinal pigment epithelial cell line ARPE-19 with hydrogen peroxide (H2O2).

[0107] Degenerated retinal pigment epithelial cells that appear in age-related macular degeneration were set as a model cell line, and epithelial loss of retinal pigment epithelial cells was induced.

[0108]

[0109] 2) Drug dosage and administration

[0110] The experimental group for verifying the efficacy of GV1001 in reducing cell degeneration was set up as shown in Table 1 below.

[0111] Group Drug Negative control group Saline H2O2 (50 μM) Treatment group Saline GV1001 Pre-treatment 0.01 μM 0.1 μM 1.0 μM 10 μMG V1001 Post-treatment 0.01 μM 0.1 μM 1.0 μM 10 μM Metformin (1 mM)

[0112] * GV1001 pre-treatment was performed by treating GV1001 for 2 hours and then treating with H2O2 for 24 hours.

[0113] * GV1001 post-treatment was performed 2 hours after H2O2 treatment 24 hours later.

[0114] * As a positive control drug for GV1001, metformin (Met) has been confirmed to have an effect of improving oxidative stress in retinal pigment epithelial cells treated with H2O2. 1 mM was used.

[0115] * All drugs were diluted in 0.9% saline solution and used.

[0116]

[0117] 3) Verification of reduction in retinal pigment epithelial cell degeneration by GV1001

[0118] The research contents and methods for verifying the cell degeneration reduction efficacy of GV1001 using H2O2-treated retinal pigment epithelial cell line model (ARPE-19) are shown in Table 2 below.

[0119] Research content Research method Confirmation of maintenance of epithelial properties of cells by GV1001 By observing changes in Cadherin 1 (CDH-1), an epithelial cell marker, and vimentin, a mesenchymal cell marker, using a confocal microscope, the progression of epithelial-mesenchymal transition (EMT), a degeneration process of retinal pigment epithelial cells, was confirmed. Observation of regulation of oxidative stress by GV1001 Using 2',7'-Dichlorofluorescin Diacetate (DCF-DA), a reactive oxygen species dye, changes in intracellular reactive oxygen species levels by GV1001 were confirmed using a fluorescence microscope.

[0120]

[0121] 1.3 Efficacy evaluation by short-term administration of GV1001 in a mouse model of age-related macular degeneration

[0122] 1) Establishment of an animal model of age-related macular degeneration

[0123] Mice injected with sodium iodate (NaIO3) are a representative model of age-related macular degeneration. A mouse model of age-related macular degeneration was established by injecting NaIO3 into C57BL / 6 mice, inducing oxidative stress and damage specifically to retinal pigment epithelial cells.

[0124]

[0125] 2) Drug dosage and administration

[0126] The animal experimental group for verification of the efficacy of reducing retinal pigment epithelial degeneration by short-term administration of GV1001 was set up as shown in Table 3 below.

[0127] Group Drug Individual Water Negative Control Group Saline 3 NaIO 3 Treatment Group Saline 3 GV100 1 Pre-treatment 0.01 mg / kg 30.1 mg / kg 30.5 mg / kg 31 mg / kg 3 GV100 1 Post-treatment 0.01 mg / kg 30.1 mg / kg 30.5 mg / kg 31 mg / kg 3 Metformin (4 mg / mL) 3

[0128] * NaIO3 was injected once at 20 mg / kg via intravenous injection (IV injection) into the tail vein.

[0129] * GV1001 was administered 0.01, 0.1, 0.5, or 1.0 mg / kg by subcutaneous injection (SC injection) three times a week.

[0130] * For GV1001 pre-treatment, as shown in Figure 1, GV1001 was injected subcutaneously three times a week for two weeks starting from four days before NaIO3 administration.

[0131] * For GV1001 post-treatment, as shown in Fig. 2, GV1001 was injected subcutaneously three times over a period of one week starting 10 days after NaIO3 administration.

[0132] * As a positive control drug for GV1001, metformin 4.0 mg / mL, which has been confirmed to have an improving effect on retinal pigment epithelial layer degeneration caused by oxidative stress, was used. As shown in Figure 3, it was diluted in drinking water and administered while replacing it with regular water for 7 days before NaIO3 administration.

[0133] * Drugs other than metformin were diluted in saline solution and used.

[0134]

[0135] 3) Confirmation of the efficacy of GV1001 in reducing damage to the retinal pigment epithelium

[0136] To confirm whether the disruption of tight junctions in the retinal pigment epithelium caused by NaIO3 administration was inhibited by GV1001, the retinal pigment epithelium / choroid (RPE / choroid) was flat mounted, and the junctions between epithelial cells were stained with phalloidin samples and observed using a confocal microscope.

[0137]

[0138] 1.4 Evaluation of the efficacy of long-term administration of GV1001 in a mouse model of age-related macular degeneration

[0139] 1) Establishment of an animal model of age-related macular degeneration

[0140] A mouse model of age-related macular degeneration was established by inducing damage by inducing oxidative stress specifically in retinal pigment epithelial cells by injecting NaIO3 into C57BL / 6 mice.

[0141]

[0142] 2) Drug dosage and administration

[0143] The GV1001 dose determined through a short-term administration efficacy evaluation test was used for long-term administration efficacy evaluation.

[0144] The animal experimental group for verification of the efficacy of reducing retinal pigment epithelial degeneration by long-term administration (3 months) of GV1001 was set up as shown in Table 4 below.

[0145] Group Drug Individual Water-soluble Control group Saline 3 NaIO 3 Treatment group Saline 3 GV 100 1 Pre-treatment 0.1 mg / kg 3 1.0 mg / kg 3 Group Drug Individual Water-soluble Control group Saline 15 NaIO 3 Treatment group Saline 15 GV 100 1 Post-treatment 0.1 mg / kg 15 1.0 mg / kg 15

[0146] * NaIO3 was injected once via tail vein at a dose of 20 mg / kg.

[0147] * GV1001 was diluted in saline solution at 0.1 or 1.0 mg / kg and administered subcutaneously three times a week.

[0148] * For GV1001 pre-treatment, as shown in Figure 4, GV1001 was injected subcutaneously three times a week for 12 weeks starting 10 weeks before NaIO3 administration.

[0149] * For GV1001 post-treatment, as shown in Figure 5, GV1001 was injected subcutaneously three times a week for 10 weeks starting two weeks after NaIO3 administration.

[0150]

[0151] 3) Confirmation of the efficacy of GV1001 in reducing damage to the retinal pigment epithelium

[0152] To determine whether the disruption of tight junctions in the retinal pigment epithelium was inhibited by GV1001, the retinal pigment epithelium / choroid was flat-mounted, and the junctions between epithelial cells were stained with phalloidin-stained samples and observed using a confocal microscope to determine the degree of tight junction disruption.

[0153]

[0154] 2. Experimental Results

[0155] 2.1 Verification of reduction in retinal pigment epithelial cell degeneration by GV1001

[0156] 1) Reduction of reactive oxygen species by GV1001

[0157] Using DCF-DA, a reactive oxygen species staining sample, changes in the level of reactive oxygen species in retinal pigment epithelial cells (ARPE-19) induced by GV1001 were confirmed by fluorescence microscopy, and the results are shown in Fig. 6. DCF-DA fluorescence expression increased when oxidative stress was induced by H2O2, but decreased by treatment with metformin, a positive control.

[0158] Under oxidative stress conditions, DCF-DA fluorescence expression decreased at a concentration of 0.01 μM when GV1001 was pre-treated, and at concentrations of 0.1 μM and 10 μM when GV1001 was post-treated.

[0159] The increase in reactive oxygen species observed when retinal pigment epithelial cells are subjected to oxidative stress can be suppressed or reduced by GV1001. This confirms that GV1001 enables retinal pigment epithelial cells to resist oxidative stress.

[0160]

[0161] 2) Reduction of retinal pigment epithelial cell degeneration by GV1001

[0162] The degree of epithelial-mesenchymal transition, which indicates degeneration of retinal pigment epithelial cells, was confirmed by observing changes in cadherin 1, an epithelial cell marker, and vimentin, a mesenchymal cell marker, using a confocal microscope, and the results are shown in Figure 7.

[0163] We confirmed that oxidative stress induced by H2O2 decreased the expression of epithelial cell markers and increased the expression of mesenchymal cell markers, thereby promoting epithelial-mesenchymal transition. When metformin, the positive control, was treated, epithelial-mesenchymal transition was reduced.

[0164] Epithelial-mesenchymal transition was reduced at a concentration of 0.01 μM in pre-treatment with GV1001 and at a concentration of 10 μM in post-treatment.

[0165] The epithelial-mesenchymal transition observed when retinal pigment epithelial cells are subjected to oxidative stress can be inhibited or reduced by GV1001. This confirms that GV1001 enables retinal pigment epithelial cells to maintain or restore epithelial properties.

[0166]

[0167] 2.2 Efficacy evaluation by short-term administration of GV1001 in a mouse model of age-related macular degeneration

[0168] To determine whether the disruption of tight junctions in the retinal pigment epithelial cell layer is inhibited by GV1001, the retinal pigment epithelial layer / choroid was flat-mounted, and the junctions between epithelial cells were stained with phalloidin and observed using a confocal microscope. The results are shown in Figures 8 and 9.

[0169] In the NaIO3-treated group, the tight junction structure of the retinal pigment epithelial cell layer was significantly damaged, indicating a loss of epithelial function and a well-established mouse model of macular degeneration. When treated with metformin, the GV1001 positive control, the tight junction structure was maintained.

[0170] Tight junction structures of the retinal pigment epithelial cell layer were maintained at 0.1 mg / kg pre-treatment with GV1001, and at 0.5 and 1.0 mg / kg post-treatment. This confirmed that GV1001 maintains or restores the epithelial properties of retinal cells in a mouse model of age-related macular degeneration.

[0171]

[0172] 2.3 Evaluation of the efficacy of long-term administration of GV1001 in a mouse model of age-related macular degeneration

[0173] To determine whether long-term administration of GV1001 reduces the disruption of tight junctions in the retinal pigment epithelium, the retinal pigment epithelium / choroid was flat-mounted, and the junctions between epithelial cells were stained with phalloidin and observed using a confocal microscope. The results are shown in Figures 10 and 11.

[0174] In the NaIO3-treated group, the tight junction structure of the retinal pigment epithelial cell layer was significantly damaged, indicating loss of epithelial properties, and it can be seen that the macular degeneration mouse model was well established.

[0175] As shown in Fig. 10, in the case of GV1001 pre-treatment, when GV1001 was administered long-term at 0.1 mg / kg or 1.0 mg / kg, the tight junction structure of the retinal pigment epithelium layer was well maintained, so that cell membrane collapse due to epithelial layer degeneration did not occur, and one nucleus per closed junction cell membrane was observed.

[0176] As shown in Fig. 11, in the case of GV1001 post-treatment, when GV1001 was administered long-term at 0.1 mg / kg or 1.0 mg / kg, the tight junction structure of the retinal pigment epithelium layer was well maintained, so that cell membrane collapse due to epithelial layer degeneration did not occur, and one nucleus per closed junction cell membrane was observed.

[0177]

[0178] 3. Conclusion

[0179] 3.1 Verification of reduction in retinal pigment epithelial cell degeneration by GV1001

[0180] (1) Reduction of reactive oxygen species by GV1001

[0181] The increase in reactive oxygen species observed when oxidative stress is applied to retinal pigment epithelial cells can be suppressed or reduced by GV1001. This suggests that GV1001 enables retinal pigment epithelial cells to combat oxidative stress.

[0182]

[0183] (2) Reduction of degeneration of retinal pigment epithelial cells by GV1001

[0184] The epithelial-mesenchymal transition observed when oxidative stress is applied to retinal pigment epithelial cells can be inhibited or reduced by GV1001. This suggests that GV1001 reduces degeneration of retinal pigment epithelial cells and maintains or restores epithelial properties.

[0185]

[0186] 3.2 Efficacy evaluation by short-term administration of GV1001 in a mouse model of age-related macular degeneration

[0187] Short-term pre- or post-treatment with GV1001 in a mouse model of age-related macular degeneration (AMD) resulted in reduced retinal pigment epithelial degeneration and maintenance or restoration of epithelial integrity. This confirmed the excellent preventive and / or therapeutic efficacy of GV1001 against age-related macular degeneration.

[0188]

[0189] 3.3 Evaluation of the efficacy of long-term administration of GV1001 in a mouse model of age-related macular degeneration

[0190] Long-term pre- or post-treatment with GV1001 in a mouse model of age-related macular degeneration (AMD) resulted in reduced retinal pigment epithelial degeneration and maintenance or restoration of epithelial integrity. This confirmed the excellent preventive and / or therapeutic efficacy of GV1001 against age-related macular degeneration.

Claims

1. A pharmaceutical composition for preventing or treating macular degeneration, comprising a peptide having an amino acid sequence of sequence number 1.

2. A pharmaceutical composition according to claim 1, wherein the macular degeneration is age-related macular degeneration.

3. In claim 1, the pharmaceutical composition prevents or treats macular degeneration by reducing degeneration of retinal pigment epithelial cells.

4. A pharmaceutical composition according to any one of claims 1 to 3; and A kit for the prevention or treatment of macular degeneration, comprising instructions describing a method for the prevention or treatment of macular degeneration.

5. A kit according to claim 4, wherein the method for preventing or treating macular degeneration comprises a step of administering the pharmaceutical composition to a subject who has developed or is at risk of developing macular degeneration.

6. A health functional food for preventing or improving macular degeneration, comprising a peptide having an amino acid sequence of sequence number 1.

7. A health functional food according to claim 6, wherein the macular degeneration is age-related macular degeneration.

8. In claim 6, the health functional food is a health functional food that prevents or improves macular degeneration by reducing degeneration of retinal pigment epithelial cells.

Citation Information

Patent Citations

  • Peptide for inhibiting HSP expression and composition containing same

    KR1020160009548A

  • Peptides for treating ophthalmopathy and the Composition Comprising the Same

    KR1020160076911A

  • Peptide having angiogenesis inhibitory activity and composition containing same

    KR1020160079881A

  • Virtual assetization device for software training deliverables

    KR102534785B1